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T 
hough the first association between HLA and disease 
was established with an HLA class I molecule (1), the 
majority of HLA-disease associations  have been with HLA 
dass II molecules (2). Despite the awareness of such associations 
for nearly two decades,  the pathophysiological role of HLA 
class II molecules in conferring susceptibility to the associ- 
ated diseases remains poorly understood. One impediment 
to enhancing our understanding has been the inability to 
study the function of human class  II molecules in animal 
models where experimental manipulations  can be readily 
accomplished. 
Two papers  in  this issue of The Journal of Experimental 
Medicine, by Woods et al. (3) and Yamamoto et al. (4), now 
document  the  successful  construction  of transgenic mice 
bearing chimeric or whole human DR and DQ molecules, 
and further demonstrate that murine T  cells are capable of 
recognizing antigenic peptides presented by human class II 
molecules. In addition,  the results obtained by Yamamoto 
et al.  (4) dispel the notion that murine CD4 on murine T 
cells cannot function as an adequate accessory molecule during 
peptide presentation by human class II molecules. This concept 
has undoubtedly slowed progress in this much needed area. 
T lymphocyte activation is initiated through recognition 
of a peptide-MHC molecule ligand residing on the antigen- 
presenting cell by the antigen-specific receptor residing on 
the T lymphocyte. However, optimization of the activation 
is  achieved  through  a  series  of  accessory  and  adhesion 
molecules, among which is the CD4 molecule (5). CD4 was 
initially identified on the surface of a subset of T lymphocytes 
by monoclonal antibodies, and its presence was used to study 
the  functions  of this  subset.  Antibodies  against  the  55- 
kilodalton CD4 glycoprotein were demonstrated to block the 
majority  of  helper  T  cell  functions,  including  mixed 
lymphocyte reactions and induction of helper activity (6-8). 
These observations suggested that CD4 was therefore a marker 
for the helper T cell population. However, several laboratories 
subsequently demonstrated that the subset of cytotoxic T cells 
that recognized class II molecules bore CD4 (9, 10) and that 
monoclonal antibodies to CD4 could block the function of 
any T cells specific for class II molecules (11). These findings 
led to the currently held concept that CD4 positive T cells 
possess receptors that recognize peptide in the context of class 
II molecules, irrespective of their functions. 
CD4 was demonstrated to interact with class II molecules 
both by functional studies and direct binding (12,  13). The 
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two membrane-distal extracellular domains of CD4 (14, 15) 
bind  to  the 32  domain  of class  II  molecules (16-18)  on 
antigen-presenting cells,  whereas the intracellular domain 
mediates signaling together with the T  cell receptor/CD3 
complex on the T cell. The CD4 molecule thus is associated 
simultaneously  with  both  constituents  of  the  T  cell 
receptor-class II molecule recognition unit involved in antigen 
presentation. This association leads to activation of the p56 lck 
kinase and the initiation of the signaling cascade within the 
T  cell (19-21). 
Because of the critical role played by CD4 in the process 
of T cell activation, the possibility that a species barrier might 
exist between CD4 and class II raised serious concerns re- 
garding the usefulness of transgenic mice bearing human class 
II molecules as models for studying HLA class II-related dis- 
eases. The studies investigating the interaction of CD4 and 
class II molecules across species have yielded conflicting results 
to date. Lamarre et al. (15) suggested that murine CD4 prob- 
ably did not recognize HLA-DP, and Vignali et al. (16) demon- 
strated that mouse CD4 T cells reacted less well with antigen- 
presenting cells bearing an I-A molecule where the native 
32 domain was substituted with DR32.  In contrast, von 
Hoegen et al.  (22) showed that routine CD4 loss variants, 
transfected with either human or mouse CD4,  gave func- 
tionally comparable results. Results in vivo in transgenic mice 
have not resolved the issue. Single DRa transgenic mice, in 
which the DRol chain associates with the I-E3 chain, func- 
tion normally in their ability to delete T cell receptor V311 
T cells (23). This result is not surprising in light of the site 
of interaction  of CD4  with  the  murine I-E  32  domain. 
More surprisingly, single DQ3 chain transgenics were also 
shown capable of normally depleting V311 cells, suggesting 
an effective interaction between human HLA-DQ  32  do- 
mains and murine CD4 (24). In contrast, in double DQ ~/3 
transfectants, in which the transgenic DQ molecule acted as 
a restricting element, anti-mouse class II antibodies which 
were shown not to recognize the DQ molecule, nonetheless in- 
hibited the T cell response to DQ-presented peptides. These 
observations suggested that the murine CD4 might be inter- 
acting  with  murine  class  II  molecules  on  the  antigen- 
presenting cells rather than with the DQ3 chain itself (25). 
Furthermore,  in  transgenic  mice  bearing  human  CD4, 
xenogeneic T cell responses to human class II molecules on 
exogenous cells were enhanced up to 10-fold over those of 
nontransgenic mice, whereas the response to allogeneic mu- 
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ever, even in this situation, responses to human class II mole- 
cules  remained  lower  than  responses  to  murine  class  II 
allogeneic molecules, suggesting that optimal T cell responses 
require the CD4 and class II molecule to be of the same spe- 
cies  (26). 
The aforementioned papers (24-26) raised the additional 
issue of whether the T  cell receptors on T  cells from trans- 
genic mice bearing human class II molecules can effectively 
recognize those human class II molecules as antigen-presenting 
elements. This question was partially answered in the affirma- 
tive for DQ molecules in which DQ or//5 double transgenics 
were shown capable of presenting streptococcal cell wall an- 
tigen to autologous T  cells (25).  However, data regarding 
the ability of DR molecules to function in a transgenic model 
have been lacking. 
This situation has now been remedied as evidenced by the 
two papers by Woods et al.  (3) and Yamamoto  et al.  (4). 
Woods et al. (3) have attempted to circumvent the unresolved 
question  of cross-species interaction  of murine  CD4  and 
human DR molecules by constructing chimeric DR/I-Eot 
and DR/I-E~  chains in which the or1 and fll domains are 
from DR molecules, and the or2 and/~2 domains are derived 
from I-E molecules. Thus, the murine CD4 should have op- 
timal  interaction  with  the/82  domain.  Using this  system, 
these  investigators  demonstrated  that  the  DR  molecules 
influenced the T  cell repertoire by depleting VBll-bearing 
T  cells, and can act as restricting elements, presenting both 
synthetic peptides and peptides derived from processed pro- 
tein antigens  to antigen-reactive  T  cells.  Thus,  clearly,  the 
murine T cell repertoire is capable of recognizing DR mole- 
cules, and can be molded to positively select such a popula- 
tion  of T  cells. 
In the second paper,  Yamamoto et al.  (4)  have attacked 
the question of cross-species interaction  directly,  and con- 
structed a transgenic mouse expressing routine CD4 and trans- 
genic DR molecules. Here, too, the authors were able to dem- 
onstrate the flexibility of the murine T cell receptor repertoire, 
and the selection ofT cells bearing receptors capable of recog- 
nizing DR-presented antigens.  They were further able to show 
that anti-murine CD4 antibodies could inhibit these responses. 
This result dearly indicates that the interaction  between murine 
CD4 and human class II molecules is sufficient to support 
a T  cell response. 
Whereas both papers present impressive results that will 
undoubtedly influence the construction of other HLA class 
II transgenics, they unfortunately both beg the initial ques- 
tion of whether a species  difference between the CD4 and 
class II molecules in vivo diminishes the resulting immune 
response. Comparison of the T cell responses in a transgenic 
mouse bearing DR molecules versus those T  cell responses 
in a transgenic mouse bearing chimeric DR molecules should 
address the question of whether the T  cell response varies 
with the species  origin of the ~2 domain.  In addition,  the 
testing  of a  DR,  human  CD4  transgenic,  murine  CD4 
knockout (Karr,  R., X.-T. Fu, J. Strauss-Schoenberger, and 
J. Goelner, manuscript in preparation) will elucidate the re- 
quirements  for optimal  T  cell responses. 
With the possibility now at hand of constructing SCID 
mice bearing human class II transgenes, it might also be feasible 
to introduce human T cells from the blood or affected tissues 
of diseased patients into mice. A SCID/hu transgenic system 
of this  kind has the potential  to reproduce human  disease 
in a mouse model, and to allow much needed insights into 
the pathophysiologic role of human class II molecules in au- 
toimmune  disease. 
Nonetheless, the demonstration that human class II mole- 
cules can function as antigen-presenting  molecules in vivo 
in a transgenic  murine  system paves the way to  address a 
number of questions.  Perhaps most significantly,  the avail- 
ability of such mice will allow the exploration of the basis 
for the predisposition of HLA class II molecules to partic- 
ular autoimmune  diseases. 
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